A single BNT162b2 dose protects against SARS-CoV-2: A case report of a family cluster of COVID-19.

Background. Coronavirus 2019 (COVID-19) disease is an infectious caused by the virus "Severe Acute Respiratory Syndrome 2" (SARS-CoV-2). This generated a pandemic in 2020 and has affected millions of people worldwide. Facing need to prevent its contagion, vaccine BNT162b2 was approved December Mexico started administered healthcare workers. Case presentation. We presented here, two workers vaccinated with one single dose BNT162b2, who lives family nucleus high transmission rate SARS-CoV-2. These workers, identified manuscript as patient E F, were asymptomatic their real-time RT-PCR test for SARS-CoV-2 resulted negative, while rest (patients A-D) positive. The antibody titers IgG anti-spike F (after second dose; 1080 Au/mL) turned out greater than (before 37.1 Au/mL). Discussion. To our knowledge this first case report protective effect context rates within nucleus. Despite changes induced or double vaccination, showed be sufficient immunization patients against COVID-19.